Use of oxytocin for the preparation of a pharmaceutical...

Details Use of oxytocin for the preparation of a pharmaceutical... Use of oxytocin for the preparation of a pharmaceutical...

2002-02-28

2008-07-29

Tsang, Cecilia J. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C514S009100, C514S015800, C514S016700, C530S300000, C530S317000, C530S328000, C530S329000

Reexamination Certificate

active

07405200

ABSTRACT:
A method of treating cancer in situ and cervicitis is disclosed. A pharmaceutical composition comprising at least one substance with oxytocin activity against cancer in situ and cervicitis and compound of the formula SEQ ID NO:2 is also disclosed.

REFERENCES:
patent: 4402942 (1983-09-01), Melin
patent: 6262021 (2001-07-01), Uvnas-Moberg et al.
patent: 42 36 293 (1993-03-01), None
patent: 4229878 (1994-03-01), None
patent: 4244639 (1994-07-01), None
patent: WO9843660 (1998-10-01), None
patent: WO9843661 (1998-10-01), None
patent: 00/18424 (2000-04-01), None
patent: WO 200018424 (2000-04-01), None
patent: 01/78758 (2001-10-01), None
patent: WO 03017922 (2003-06-01), None
D. Kornfeld, et al. Gut. (1997) 41, pp. 522-525.
J.A. Eaden, et al. Gut. (2001) 48, 526-535.
A. Ekbom, et al. N. Engl. J. Med. (1990) 323(18), pp. 1228-1233.
B. Jancin. “Data from two studies: fibromyalgia patients may have higher Ca risk.” OB/GYN News Sep. 15, 2004, 2 pages.
K.B. Michels, et al. Diabetes Care (2003) 26(6), pp. 1752-1758.
R. Talamini, et al. Brit. J. Cancer. (1997) 75(11), pp. 1699-1703.
M.E. DelGiudice, et al. Breast Cancer Res. Treat. (1998) 47, pp. 111-120.
Gianni Bussolai et al., “In-labeled 1,4,7,10-Tetraazacyclododecane-N,N′,N″,N′″-tetraacetic Acid-Lys8-Vasotocin: A New Powerful Radioligand for Oxytocin Receptor-expressing Tumors,” Cancer Research, V. 61, 2001, pp. 4393-4397.
Paola Cassoni et al., “Oxytocin Receptors in Human Adenocarcinomas of the Endomtrium: Presence and Biological Signifcance,” Journal of Pathology, V. 190, 2000, pp. 470-477.
STN International, File CA, Chemical abstracts, accession No. 111:233675, Petr Simek et al., “Preparation of [2- (0-methyltrosine)] deamino-1-carbaoxytocin by a combined solid phase and solution method,” 1998, two pages.
STN International, File CAPLUS, CAPLUS accession No. 1969:47836, document No. 70:47836, Haruhiko Aoyagi et al., “Analogs of oxytocin containing leucinamide and glycylcinamide in place of glycinamide,” & Bull. Chem. Soc. Jap., 1968, V. 41, pp. 2772-2776.
STN International, File CA, Chemical abstracts, accession No. 90:6683, Roger Freidinger et al., “Titanium (III) as a selective reducing agent for nitroarginyl peptides: synthesis of arginine vasotocin,” & J. Org. Chem., 1978, V. 43, pp. 4800-4803.

Affiliated with

Also associated with

Rating

Use of oxytocin for the preparation of a pharmaceutical... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of oxytocin for the preparation of a pharmaceutical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of oxytocin for the preparation of a pharmaceutical... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3967852